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Markets under the Microscope: 
Making Scientific Discoveries Valuable through Choreographed Contestations 
 
ABSTRACT 
This paper breaks new ground by revealing and conceptualizing the marketization of science 
as a process that transforms scientific discoveries and markets through a series of 
choreographed contestations: moments of valuation that occur when different social worlds 
collide. We follow a scientific discovery, from the moment it entered an incubator, to uncover 
how valuation practices and market devices enact and contest diverse social values (i.e., what 
is worth doing) to generate economic value (i.e., what is worth paying for) at the science-
market-entrepreneurship nexus.  In contrast with commercialization of science studies that 
focus on institutional arrangements, this study explicates the practices and devices used by 
multiple market actors to transform a scientific discovery into a marketable object. In so doing, 
we characterise choreographed contestations and the mechanisms through which they operate 
to explain how specific valuations are performed to work out innovative next steps that unfold 
the marketization of science. 
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The market for cancer treatments is dominated by chemotherapies. Chemotherapies attack 
every dividing cell they encounter, often resulting in undesirable side effectsi. Scientists are 
now seeking antibody-based therapies, which only target cancer cells.  Much of this early stage 
scientific work takes place in university laboratories, but the discoveries must emerge from 
these non-commercial settings if they are to become both socially and economically valuable.  
However, we know little of the practices that support the commercialization of such scientific 
discoveries, or how markets shape this process.  
The commercialization of science is understood as the exploitation of a scientific invention 
to reap financial rewards (Perkmann et al. 2013), making science valuable and marketable. 
However, scientific discoveries are not always immediately associated with the problem they 
ultimately address: when patients reported the surprising side effects of Sildenafil Citrate (an 
angina therapy), Pfizer re-marketed it as Viagra - a treatment for erectile dysfunction (Loe 
2004). Discoveries emerging from settings where commercialization and market expertise is 
lacking have provoked research identifying the institutional arrangements and resources needed 
to support science commercialization: intellectual property rights protection (Debackere and 
Veugelers 2005; Lockett et al. 2002; Lockett and Wright 2005), licencing agreements support 
(Lockett and Wright 2005; Siegel et al. 2003), and setting-up/monitoring spin-outs (Clarysse et 
al. 2007; Vohora et al. 2004). Yet we still know little of how commercialization forges market 
connections (Cooke 2001) essential for progression from embryonic science to economically 
valuable, market object.  
The market studies literature conceptualizes markets as socio-economic collectives that 
contest, calculate and co-ordinate action, organizing multiple social values to generate 
economic value (Geiger et al. 2014; Stark 2009). Through this co-ordination markets enable 
compromises on the nature and value of goods produced  (Araujo 2007; Callon and Muniesa 
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2005). This suggests that commercializing any good requires connecting distributed and 
heterogeneous sets of expertise to work out what is valuable, to whom and why. The process 
by which this happens is referred to as marketization (Araujo and Pels 2015; Çalışkan and 
Callon 2010). By studying the marketization of science, we shift from the commercialisation 
of science literature’s focus on institutional support for academic entrepreneurs, to the 
collective valuation of scientific discoveries through the engaged and contested practices of 
multiple market actors.   
Adopting this approach, we see markets as being constructed through collective market 
action (Callon and Muniesa 2005), and seek to uncover the process through which this action 
transforms both the scientific discovery and the market it seeks to enter. To uncover the tensions 
that academic-scientists face in this process (Clarysse et al. 2007; Cooke 2001; Vohora et al. 
2004), we draw on social worlds theory to explicate the plurality of norms, discourses, symbols 
and practices (Clarke and Star 2008; Strauss 1978) brought together in market encounters. 
Fisher, Kotha and Lahiri (2016) recognise this plurality in the way new ventures secure 
resources from different audiences, arguing that social judgements and valuations reside within 
socially constructed systems of norms, values, and beliefs. We suggest that the ways in which 
market encounters are organised and performed is critical to the marketization of science, and 
particularly the way they produce multiple and sequential moments of valuation at the nexus 
of multiple social worlds. In this paper we ask: In the process of marketization, how do 
contestations between different market actors make scientific discoveries valuable? 
We elaborate theory (Maitlis 2005) through a single, longitudinal case study of ‘AntiBod’, 
a scientific discovery typical of those incubated at the Stevenage Bioscience Catalyst (SBC), 
in the UK. This allowed us to generate ‘thick descriptions’ (Geertz 1973) of  how AntiBod  was 
made valuable, revealing the complex and pluralistic valuation practices performed in the 
marketization of science.  
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We find that there is no predetermined marketization pathway. Rather, a series of 
choreographed contestations unfolds at the nexus of social worlds, transforming the scientific 
discovery into a marketable, economically valuable object. Each contestation brings together 
valuation practices and market devices from multiple social worlds to temporarily frame and 
fix what is being valued and how. By holding these devices and social worlds in dialogue, new 
valuations are produced, shaping understandings of what is worth doing next. How 
marketization is achieved only becomes apparent as each moment of valuation unfolds the next; 
as the dissonance created through the collision of discourses, symbols and understandings of 
social worlds is surfaced productively and acted upon, one innovative step at a time. 
We extend understanding of the commercialization of science by introducing a conceptual 
framework of choreographed contestations to explain how marketization occurs through the 
generative interplay of valuation practices and market devices from diverse social worlds. This 
shifts our attention away from institutional arrangements and towards the practices and devices 
that perform the collective working out of innovative next steps in the marketization process 
(Callon and Muniesa 2005; Pénet 2015; Pollock and D’Adderio 2012). These insights take us 
beyond recognition of the challenges and tensions typically experienced by academic-
entrepreneurs (Siegel et al. 2003; Siegel and Wright 2015a), by foregrounding the role of 
collective valuation practices in ‘disentangling’ discoveries from extant social worlds and 
norms in order to make them valuable in markets. Our paper concludes by discussing how our 
theories from the lab have broader implications for management research. 
LITERATURE REVIEW 
The Commercialization of Science 
Much commercialization of science literature focuses on understanding university spin-offs 
and the institutional environments that shape them, addressing issues such as the impact of 
equity investment availability (Lockett and Wright 2005), business development capabilities 
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and royalty regimes of university technology transfer offices (TTOs) (Lockett and Wright 2005; 
Siegel et al. 2003), and network capabilities progressively developed by spin-offs (Baraldi et 
al. 2014; Walter et al. 2006). This work foregrounds the significance of creating a credible 
venture, and the importance of context, particularly the significance of TTOs within universities 
(Clarysse et al. 2007; Lockett and Wright 2005; Lockett et al. 2003). TTOs stimulate 
entrepreneurial activity and are responsible for registering patents, organising licencing 
agreements and establishing spin-outs as independent companies in which intellectual property 
(IP)-owning universities have a stake (Lockett et al. 2003). As such, they are seen as ‘insiders’ 
with specific skill-sets and expertise (Lockett and Wright 2005, p.1047), organising key 
evaluative processes before commercialization commences (Vohora et al. 2004). In sum, this 
institutional approach looks at the organisation and structure of resources and the organisational 
routines put in place by universities to help academic entrepreneurs commercialize discoveries 
(Dodgson et al. 2011; Lockett et al. 2002; Perkmann et al. 2013; Roseira et al. 2014).  
 Perkmann et al. (2013, p.424) see ‘the founding of a firm with the objective to 
commercially exploit a patented invention or in some cases, a body of unpatented expertise’ as 
a ‘preliminary step indicating a disposition on the part of the academic towards some kind of 
exploitation’. The context of university spin-outs is distinctive because it involves the 
development of business opportunities based on unique forms of disruptive technologies 
coupled with tacit knowledge from academic research (Rasmussen et al. 2011). The academic 
often continues to work for the university, which retains IP post spin-out (Siegel and Wright 
2015a), creating tensions for academics, since they ordinarily adopt traditional scientific norms, 
standards and values that contrast sharply with conventional entrepreneurial activities (Siegel 
et al. 2003). Through commercialization, academics step into new and unfamiliar social worlds 
of management, entrepreneurship and market development that have different social norms and 
values to their own (cf. Siegel and Wright 2015a). To date, there is little explication of the 
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impact these multiple ‘social worlds’ have on scientific discoveries, as the worlds of academia, 
commerce, business, management and markets collide. Each social world has unique sites of 
practice, patterned commitments, practices, technologies, and associated ways of organising 
(Baszanger 1998; Bucher 1962) and so values differently. As Rasmussen, Mosey, and Wright 
(2011, p.1315) observe, ‘academic spin-off ventures therefore require the creation of new 
development paths that depart from existing practices’. To gain a deeper understanding of these 
new paths, through multiple social worlds with multiple practices, we turn to market studies. 
From Commercialization to the Marketization of Science: A Conceptual Framework 
In the market studies literature, markets are conceptualized as categories of goods (e.g., 
healthcare diagnostics or therapeutics); often, these categories are multiple, contradictory, and 
dynamic (Kjellberg et al. 2015). This means that the transformation of markets is never clear-
cut. However, actors’ conceptualizations of markets are at least partially reconciled through the 
coordinated, collective actions and devices that constitute them (Azimont and Araujo 2007). 
This includes the institutionalizing norms and rules, technical devices and infrastructures, 
images, models, and representations of scientific and market knowledge, and enacted practices 
and routines that constitute each market category (Çalışkan and Callon 2010; Kjellberg et al. 
2015). Markets are the ongoing socio-technical accomplishments that depend on the 
mobilization of varying bodies of expertise, calculative agencies, devices, and practices (Callon 
and Muniesa 2005); and the work of marketing (i.e., the practice of making and shaping 
markets) as the distributed and heterogeneous sets of agencies involved in the process of 
facilitating market exchange and constructing market institutions (Araujo 2007). Callon and 
Muniesa (2005, p.1229), conceptualizing marketing in terms of valuing: ‘markets are collective 
devices that allow compromises to be reached, not only on the nature of goods to produce and 
distribute but also on the value given to them’, while Doganova and Muniesa (2015, p.120) see 
the work of bringing these collectives together as a form of ‘choreography’. Such 
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conceptualizations emphasize the distributed nature of expertise and imply that multiple market 
actors are deliberately brought together to value and make things valuable.  
We draw on the commercialization and market studies literatures, together with social 
worlds theory and our empirical data, to offer a framework for understanding how markets 
make scientific discoveries valuable (Figure 1).  This abductively derived framework brings 
together concepts from these disparate literatures, representing our contributions:  
conceptualising choreographed contestations at the nexus of social worlds as the mechanism 
that unfolds the marketization of science.  Our conceptualisation shows the fixing and framing 
of valuations and the generative dialogue between valuation practices and market devices at 
this nexus. We introduce our conceptual framework here, before explaining the abductive 
process of its construction (Methods Section).  
------------------------------------------- 
INSERT FIGURE 1 ABOUT HERE 
------------------------------------------- 
Valuation practices: We draw on the market studies literature in our conceptualization of 
valuation practices. Valuation practices make things socially and economically valuable 
(Kornberger et al. 2015). They are the routine and recursive practices that collectively 
determine how new goods are conceptualized, produced and exchanged, as distributed market 
actors come together to contest and decide what is worth doing, how (by whom) and why 
(Araujo and Pels 2015; Dussauge et al. 2015; Stark 2000). Both social and economic value(s) 
are implicated in this marketization process. Because the market studies literature focuses on 
the world of the market, we additionally draw on social worlds theory (Clarke and Star 2008) 
to understand how market actors value differently (Dussauge et al. 2015; Fisher et al. 2016). 
Values from different social worlds, when brought together, are likely to create contestations 
that produce negotiated outcomes through efforts to create economic value. While many social 
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worlds may be encountered in different contexts, those represented in Figure 1 are most 
important in this case, as inductively identified through our data.  
The study of valuation practices, then, is the study of how things are made commensurate, 
compared, categorized, and clarified; of how some things are judged to count more than others. 
It is through valuation practices that the market is ordered, hierarchized, and ultimately valued 
(Kornberger 2017). This seems particularly pertinent in uncertain marketization settings where 
the anticipatory nature of scientific and market knowledge requires a pragmatic approach to 
working out what is plausible and what knowledge should be pursued next (Pénet 2015), using 
what devices. The devices used in these valuation practices vary, depending on which actors 
invoke them and why; we consider these next. 
Market devices: Valuation practices make use of and generate market devices that value 
(Kjellberg et al. 2015). Muniesa et al. (2007, p.2) describe market devices as ‘the material and 
discursive assemblages that intervene in the construction of markets’, offering examples to 
illustrate the breadth of market devices, including analytical techniques, pricing models, 
merchandising tools, and trading protocols. Market devices might be technical or epistemic. 
Cochoy (2009) describes how the introduction of the shopping trolley (a technical market 
device) facilitated in-store transport of larger volumes of goods, equipping shoppers to make 
different valuations about what to buy, thus changing market behaviour. In contrast, Pollock 
and D’Adderio (2012) showed how framing a market using Gartner’s Magic Quadrant (an 
epistemic market device) mediates and constitutes a particular market domain. They argue that 
material things (including market representations) and markets come to constitute one another. 
Thus, market devices are often representations of market, scientific or technical knowledge, 
enabling actors to understand, calculate or work out states of the world. These examples reveal 
the multiple and adaptable nature of market devices as they are re-presented to different social 
worlds to work out different forms of value (cf. Fisher et al. 2016). 
10 
 
Choreographed contestation at the nexus of social worlds: The notion of contestation is 
central to the understanding of markets and their valuation practices. Contestations are 
understood as the process of disputing or arguing, which often characterises key moments of 
valuation in which social, economic and political issues are explored and settled (Antal et al. 
2015). Stark (2009) views contestation as a form of search where actors struggle with the 
indeterminate nature of discovery (Dewey 1938), since actors may not know what they are 
looking for. In the marketization of science, the potential ‘therapeutic target’ (e.g., HER2 or 
breast cancer) for a protein or antibody may remain unknown and unspecified for a considerable 
length of time (Osta et al. 2004). This is commensurate with observations that many TTOs in 
universities design processes that incorporate routine contestations whereby ideas can be 
interrogated, critiqued and explored, so that new searches for information, data and/or resources 
can be decided on (see Lockett et al. 2002; Lockett and Wright 2005). Stark (2009) argues that 
the deliberate organising of internal organisational contestations among a variety of actors can 
be central to success, precisely because contestations allow different values to be identified, 
explored, and ordered. Doganova and Muniesa (2015, p.120) see the ‘choreography’ of such 
contestations as critical in the marketizing process but provide little conceptual guidance. Thus, 
studying contestations at the nexus of multiple social worlds to understand how they are 
choreographed and what these choreographies do is likely to reveal deeper understandings of 
the marketization of scientific discoveries. 
METHOD 
This research used a qualitative methodology, which is well suited to the study of dynamic 
processes and the coordinated practices of multiple actors (Denis et al. 2007; Langley 2007). 
Because this type of qualitative, process research typically follows an object of change (Latour 
1987), it is particularly sensitive to context, presenting a valuable means to focus on unfolding 
practices at the juncture where organisations encounter external market actors. 
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The aim of this study was theory elaboration, drawing on and extending important ideas 
from extant commercialization of science and market studies research. Theory elaboration is 
used when pre-existing ideas provide the foundation for a new study, without the need for 
purely inductive or grounded analysis (Maitlis 2005). This paper draws on an eighteen-month, 
longitudinal analysis of a single scientific discovery (AntiBod), situated in a bioscience 
incubator (SBC), and enrolled in a marketization process. We paid particular attention to the 
incubator context and to AntiBod’s multiple, unfolding market encounters and their outcomes 
in a process of marketization (Langley et al. 2013; Latour 1987; Stark 2009). This design 
offered a strong foundation for elaborating theory: the initial study of the bioscience incubator 
setting allowed the meaningful comparison of social processes and practices involved in 
scientific discovery and bioscience incubation. The subsequent, in-depth analysis of the 
marketization of a typical scientific discovery allowed  us to uncover and examine  the 
practices, devices, and social world interactions that made the  discovery valuable (cf. Geertz 
1973).  
Research Context 
Our research question required a context where science commercialization proceeds at the 
nexus of social worlds (Clarke and Star 2008), which could be considered typical and 
representative of  wider science commercialization settings (Yin 2009). We argue that science 
incubators and the companies located within them are particularly suited as a research context. 
Incubators nurture early stage scientific discoveries and the actors involved are often 
entrepreneurs, but also scientists employed by universities and research organizations (Mian et 
al. 2016).  At the same time, incubators connect scientists to other market actors such as venture 
capitalists, consultants, and in bioscience, pharmaceutical companies (Bruneel et al. 2012), 
situating incubators at the centre of many marketization processes. As such, a nexus of social 
worlds is inherent in the day-to-day practice of science incubation. We conducted our study at 
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Stevenage Bioscience Catalyst (SBC): a not-for-profit incubator, formed in 2011 by 
GlaxoSmithKline (GSK), a major pharmaceutical company, the Wellcome Trust and the UK 
Government. SBC’s remit is to support academic-entrepreneurs and incubate scientific 
discoveries, collaborating with universities in order to do so. Through our engagement with 
SBC we identified a particular scientific discovery, AntiBod, whose marketization we were 
able to follow over time.    
Case Selection  
The specific scientific discovery - AntiBod - was chosen to meet the study’s aim: to map out 
the marketization process of a scientific discovery, to explain how it is made valuable. This 
discovery is from the largest category of the four at SBC: therapeutics. The tenancy of SBC 
comprised nineteen in therapeutics, four in manufacturing/technology, two in big data, and 
none in the diagnostics/devices category.  Marketization practices for therapeutics therefore 
represented the most widely engaged in practices at the incubator.   
During the initial stages of our study, AntiBod became a tenant at SBC.  Studying AntiBod 
represented an ideal context to elaborate marketization of science theory, for three reasons. 
First, the marketization of therapeutics was becoming increasingly routine at SBC, typically 
featuring multiple actors engaged in routine, recursive interconnected, patterned actions 
recognisable as the early stages of a marketization process (Araujo and Pels, 2015).  SBC’s 
need to develop recursive practices that perform marketization, through multiple experimental 
actions with cases like AntiBod, make AntiBod a typical case. Second, the aim of AntiBod’s 
discoverer was to marketize AntiBod. As such, the project did not revolve around the typical 
challenges associated with implementing a process: instead, the project provided a compressed 
opportunity to observe the practices associated with marketization, and more specifically in 
making specific activities and objects valuable and worth investing in (cf. Stark, 2009). Finally, 
from the outset AntiBod expressed an interest in engaging with multiple external market actors, 
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particularly other incubator tenants and GSK, suggesting opportunities to observe 
transformative market encounters at the nexus of social worlds. 
Data Collection & Analysis: An Abductive Approach  
Through our study of SBC and AntiBod we discovered that valuation practices played a 
substantial role in the process of marketization and these became the focus of our study. As 
valuation practices in a commercialization setting are a relatively unexplained phenomenon 
(Dussauge et al. 2015), we moved abductively between data collection and analysis (Charmaz 
2006; Dubois and Gadde 2002), developing our understanding of the case and related literature 
concurrently, progressing our theoretical framework as we went (Figure 1). All three authors 
were involved in fieldwork, data collection and data analysis. This contextual immersion 
allowed us to interrogate the data and discuss the emerging conceptual argument in depth. Our 
abductive approach (Charmaz 2006; Dubois and Gadde 2002) to this marketization process 
study (Langley et al. 2013) followed three overlapping stages.  
Stage One: The Marketization Context. We spent time observing events and incubation 
practices, interviewing staff, tenants and visitors at SBC. An important feature of incubation 
practice identified in this stage was that of bringing together individual academic scientists, 
pharmaceutical market development managers and bioscience entrepreneurs, each bringing 
their own devices to question and contest the marketization plans of tenants. We noticed the 
different ways in which actors understood commonly used terms (e.g. ‘markets’, ‘business 
models’, ‘data’). This led us to select social worlds theory as a ‘theory/method package’ (Clarke 
and Star 2008, p.113), guiding a systematic analysis of three key social worlds: science, markets 
and entrepreneurship. We visited and interviewed academic scientists, academic-entrepreneurs, 
as well as pharmaceutical market development managers at GSK, enabling us to identify the 
norms, practices, symbols, and where relevant, the technical tools of their everyday work. We 
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used these observations to sensitize ourselves to the different materials and understandings 
(Fujimura 1996) actors brought to the marketization process. The description of these social 
worlds forms the analytical backdrop to AntiBod’s marketization process. 
Stage Two: Following a Scientific Discovery. Having developed a broad understanding of 
the incubation context we wanted to understand particular transformative market encounters 
(Langley 1999). We worked with SBC managers to identify a typical science discovery case 
(Yin 2009) to follow through the marketization process (Latour 1992). We selected a ‘superior 
antibody’, referred to here as AntiBod. As with many scientific discoveries entering an 
incubator, AntiBod was still ‘just an idea’ and its scientific ‘proof of concept’ (SBC1) was only 
partial when we first encountered it. Drawing on interviews, documents and observational data 
we followed AntiBod for 18 months. During this time, we never knew what would happen next, 
so we treated the whole process as an inquiry into an indeterminate situation (Dewey 1938), 
recording sequential pragmatic steps as they unfolded. 
Four key concepts were used to both explain stage one observations and further develop 
our conceptual framework (Figure 1): the notion of choreography (Doganova and Muniesa 
2015) was appealing but poorly conceptualised, so we additionally drew on conceptualisations 
of valuation practices (Helgesson and Muniesa 2013; Kornberger et al. 2015) and market device 
(Kjellberg et al. 2015) to help us understand what a choregraphed contestation was and how it 
worked in practice. The fourth key concept, social worlds (Clarke and Star 2008), enables us 
to unpack relations between valuation practices, market devices and actors, revealing how and 
why these specific forms of contestations were choreographed, the types of valuations they 
performed and the outcomes they produced (Table II). We noticed how valuations shifted 
between activities (e.g. information searches), objects (e.g. IP, proof of concept data) and 
institutions (e.g. AntiBod as a limited liability, IP owning company), to generate powerful 
associations between different market actors. This happened within and across contestations. 
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Ultimately, we identified six contestations (C1-C6) that produced key moments of valuation in 
the marketization process of AntiBod (Figure 2).  
Stage Three: Conceptualising Choreographed Contestations. Finally, we compared the six 
contestations, in multiple iterations, to form a conceptual interpretation of the recursive 
interplay of market devices and valuation practices at the science-market-entrepreneurship 
nexus. This resulted in the crystallization of our conceptualisation (Figure 1) and the three 
conceptual observations (Table III).  
Summary of Data 
The abductive process described above drew on three main sources of data from a range of 
businesses connected with bioscience, SBC and AntiBod, collected over 34 months (Table I). 
  
-------------------------------------- 
INSERT TABLE I HERE 
---------------------------------------- 
Interviews: We conducted 53 semi-structured interviews (Denzin and Lincoln, 2008) with 
SBC managers, experts, tenants, and participants from ‘big pharma’ and bioscience start-ups 
at workshops we observed. These interviews evolved as the study progressed, capturing 
insights into the organizations and their interactions. In stage one we asked participants to 
describe their activities and their understandings of their work, who they met with, what they 
took into meetings, what they did as a result of meetings and what they planned to do next. This 
enabled us to collect data on valuation practices and market devices used, and to draw out the 
multiple interpretations of events that exposed the importance of social worlds as a conceptual 
lens.  We carried out regular interviews at AntiBod. Interviews were transcribed verbatim.  
Observation: By attending key events organized by SBC, we observed the nexus of 
academic, market and entrepreneurial worlds in action (Latour 1987). Specifically, we observed 
four events: two ‘Open Innovation Summits’ (which included presentations, panel discussions 
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and workshop sessions), a business model workshop, and a specialized workshop for scientists 
hosted by the Entrepreneur-in-Residence on the convergence of biosciences and information 
technology. Two authors attended each of these events and took detailed notes. Open 
Innovation Summits were video recorded, enabling in-depth analysis. 
Documentation: Forty-six documents were made available for analysis. SBC provided 
strategy documents, board minutes, slide decks, management accounts, and documents 
describing the firm’s business model and the CEO’s understanding of markets. Collectively, 
these documents provided an in-depth understanding of SBC’s operations, how it engaged in 
valuation, and communicated its role. Other documents related specifically to AntiBod, and 
included various versions of AntiBod-related presentations.  
THE MARKETIZATION OF SCIENCE: THE CASE OF ANTIBOD 
In this section we present the marketization process for ‘AntiBod’, a scientific discovery. We 
first describe the characteristics of three social worlds encountered in this process, then follow 
the marketization path of AntiBod through a sequence of six choreographed contestations at 
this nexus of social worlds (Table II).  
----------------------------------- 
INSERT TABLE II HERE 
----------------------------------- 
Three Social Worlds 
The social world of academic science involves juggling teaching, research, grant writing, and 
administrative roles such as ‘running a lab’ (Sci5), or ‘co-ordinating the MSc Programme, and 
courses’ (Sci6). The talk in offices and corridors relates to ‘organisms’, ‘antibodies’, 
‘molecular and cellular levels…pathogens’, ‘control measures [and] vectors’. Scientists talk 
of the ‘wet lab’, the ‘microscope’, and the ‘bench’. Scientific knowledge is circulated at 
conferences and through publications, which act to validate expertise and provide the 
legitimacy required to secure future funding streams. The social aspects of performing and 
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evidencing ‘good science’ and ‘scientific outputs’ are celebrated and rewarded. But what 
qualifies as good science is not always straightforward: 
‘[the goal is to publish in] Nature…recognising that it can still be a good story and 
good work but it is actually probably only of interest to people who work on 
trypanosomes. …the community was, perhaps, a bit more grounded 30 years ago. 
Now, I think everybody, because of all the promotional pressures and REF 
[Research Excellence Framework] pressures and what’s the star rating of your 
journal, everybody’s being pushed to go for that highest-ranking journal.’ (Sci5) 
The social world of the market is where market development managers (often, heads of R&D 
with strong scientific backgrounds) engage with their role-specific practices and norms: 
identifying, describing and representing markets and seeking opportunities for market 
development and commercialization. To ensure brevity and relevance to our case, we focus on 
the global pharmaceutical company GlaxoSmithKline (GSK), and more specifically the groups 
within GSK that work with academics and incubators. These groups are concerned with 
advancing science for commercial ends, working to present a clear economic understanding of 
science and its potential markets. At the UK research site, these market development managers 
work with over 2,500 scientists, and recently, with academic entrepreneurs, to explore drug 
discovery opportunities.  
While many people have PhDs, are actively engaged in scientific activities, and are 
managed by or managing other groups of scientists, they are defined by the commercial context 
where scientific talk is accompanied by talk of ‘budgets’, ‘spreadsheets’, ‘timelines’, ‘global 
demand’ ‘market size’ and ‘therapeutics’ (GSK1,7,9). GSK has well developed organisational 
practices and budgetary processes to manage multiple ongoing R&D projects. The Global Head 
of Academic Liaison is responsible for some 500 new collaboration agreements every year:  
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‘We’re not a research council or an altruistic [organization]…we have to make money 
somewhere down the line. We hopefully do that through doing world leading science 
with external people who do world leading science…there’s something in it for 
everyone…that’s how I honestly see it.’  
This social world has been described by commentators as ‘problematic’ with some claiming 
that ‘drug discovery [is] in jeopardy’ (Cuatrecasas 2006, p.2637). Six big pharma companies 
dominate the market, and struggle with an ‘inward-facing culture’ (SBC1). This underpins the 
rationale for developing better ways of connecting scientists with ‘new communities’, allowing 
them to understand, interact with, and build ‘knowledge-sharing relationships’ (GSK3) with 
those who inhabit other bioscience worlds: 
‘There’s a more explicit recognition within big pharma that you can’t afford to do 
everything yourself internally. Everyone is cutting back, shrinking their 
organisations, therefore you’ve got to go and look externally for new science, 
alternative expertise, etc.’ (Scinovo; GSK7)   
While pharmaceutical companies already had some expertise at working with university 
scientists, SBC aimed to connect more potential academic entrepreneurs with GSK.    
The social world of entrepreneurs is reflected in the founding vision and management practices 
of SBC.   The original idea of creating an incubator came from a senior GSK Vice President, 
after spending time at the Berkeley Innovation Forumii. SBC’s purpose is to promote different 
knowledge sharing practices to support scientific and business development; it opened in 2012 
to incubate scientific discoveries through academic entrepreneurship. SBC is ‘much more than 
a landlord selling space to biotech start-ups’ (SBC2), and the language of tenants and managers 
reflects this with coffee-table discussions and workshop talk referring to ‘open innovation’, 
‘partnering’ and ‘business models’ (Sci5,7,11); ‘funding’, ‘grants’ and ‘Discover-Assist’ 
initiatives play a role (SBC2,5). 
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The selection of ‘natural collaborators’ as ‘anchor tenants’ early in SBC’s life is 
indicative of the oft-heard mantra of ‘getting it’: understanding the value of being part of an 
academic-entrepreneurial community.  This is important when selecting tenants:  
If their first question is, ‘What does it cost?’ then I’m not interested. They can go 
down the road where the rents are lower; that’s fine. But if they’re excited about 
being part of the ecosystem, about the connections we can make for them, then they 
are right for us. (SBC1)  
Regular formal and informal mentoring meetings with the SBC management team provide 
access to advice. Other activities include monthly tenant lunches, short scientific presentations 
by tenants, informal ‘beer and pizza’ socials, and informal ‘cajoling’ by the CEO to engage in 
the community:  
It’s all about connections. It’s all about people at the end of the day, and you need 
all those different elements working together rather than in isolation to make that 
happen.  …the event we had yesterday, to have the industry people, the NHS 
[National Health Service] people, the investors, the clinicians, the students, all in 
one room together to make those kinds of things happen. (SBC1) 
We now look at how actors connected to these three social worlds worked together to marketize 
AntiBod. We pay particular attention to how they invoked, assigned meaning to, contested and 
generated market devices and valuations at the nexus of social worlds.  
Following a Scientific Discovery through the Marketization Process 
In April 2014, Maria, a scientist (Sci1), worked in her lab in an academic institution. As part of 
a large, 4-year funded project, she used antibodies to study the genetic pathways associated 
with Alzheimer’s disease. But there was a problem - the antibodies in the test tube were not 
labelled correctly. Sharing an academic paper by Bordeaux et al. (2010), she explained:  
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‘Antibodies are among the most frequently used tools in basic science research and in 
clinical assays, but there are no universally accepted guidelines or standardised 
methods for determining the validity of these reagents. For commercially available 
antibodies, it is clear that what is on the label does not necessarily correspond to what 
is in the tube. To validate an antibody, it must be shown to be specific, selective, and 
reproducible in the context for which it is to be used.’  
The problem of ‘antibody specificity’ led to a market search that found no solutions: ‘I had to 
invest a lot of money…£20,000, to validate antibodies for the research.’ Maria’s work, to 
develop ‘reliable, highly specified antibodies’, (Sci1) resulted in scientific discoveries, in terms 
of both the antibodies and the process to produce them. As Maria peered through her 
microscope looking for the specificities of AntiBod, she considered the market. If such highly 
specified antibodies were so valuable to her, perhaps they would be to other researchers. 
So began a process of transformation that would take AntiBod through a sequence of six 
key contestations (Figure 2), on a path from initial scientific discovery to economically 
valuable product in the therapeutics market.   
                                            ------------------------------------ 
INSERT FIGURE 2 HERE 
------------------------------------- 
C1: Contesting the initial market representation (Jan 2015) 
Maria encounters the world of entrepreneurship for the first time when she visits life-science 
incubators. ‘I looked at other incubators in the region and then the Stevenage Bioscience 
Catalyst – I didn’t want to move cities… for the time being I will not give up my academic 
position – until I know that the business … is flying.’  
At SBC Maria meets Martino, SBC’s CEO, who will become her mentor. She was asked 
to bring a two page ‘summary’ describing the business idea, the science that needs developing 
and the markets it will be of value to. ‘The size and nature of market opportunity’ are described 
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as ‘the market for diagnostic and research antibodies’ which, it is claimed, ‘has an estimated 
annual turnover of $8bn and $2bn… respectively, is highly competitive and comprises about 
300 companies with more than 350k commercial antibodies’ (BM1). Martino asks, ‘Why the 
diagnostics market? … Where did you get these figures from?.... How would your business 
model fit with this [market]?.... What don’t we yet know?... Is there a bigger picture here?’ 
Martino encourages Maria to ‘put it out there’ by speaking to others. Maria takes notes, and 
draws a diagram in the margin of the summary documents. 
There are multiple outcomes to the meeting. Martino challenges the ‘facts’ about market 
scope and scale, sending Maria to search for further market information, suggesting a meeting 
with the entrepreneur-in-residence, Helen (SBC4). Other outcomes include Maria’s adoption 
of some of Martino’s language - the ‘summary’ becomes ‘the first incarnation of our business 
model’ (BM1; Sci1); the market now has ‘scope and scale’ (Sci1). Martino persuades Maria 
that there is ‘real value’ in AntiBod being incubated at SBC, ‘…and actually there are already 
two other antibody companies …there could be a synergy within SBC for antibody production 
or validation’, (SBC1). AntiBod is now a discovery worth investing in and Maria becomes a 
tenant at SBC, getting access to labs, and management advice from her new mentor: ‘…once 
every two weeks I’m over, keep contact or go to some talks or have meetings…  Martino always 
has the bigger picture in mind….. [He] is a very open and experienced guy’, (Sci1).   
C2: Contesting how the market is represented in a grant application (Feb 2015) 
Maria, Helen (the entrepreneur-in-residence), and someone from a grant funding body (F1), 
meet. Maria shares a description and images of AntiBod, but wants to explore Martino’s 
comments about the ‘scope and scale of the market’ as this will be part of an InnovateUKiii 
‘smart’ grant application to fund AntiBod’s development. The grant scheme supports three 
types of projects ‘Proof of Market (up to £25,000 grant), Proof of Concept (up to £100,000 
grant); Development of Prototype (up to £250,000 grant)’ (InnovateUK, 2015, p. 2); it is 
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uncertain which is appropriate because Martino had questioned the scope of the ‘diagnostic 
market’; the group look at the ‘rules’:‘[…]academic institutions are not eligible. However, a 
spin-out that is less than 50% owned by its academic parent may be ….’ (InnovateUK, 2015, 
p. 3). This raised a more pressing issue – ‘so you don’t actually own the IP yet’ (SBC4).  
A discussion about IP follows. Helen talks through a patent application process and flags 
this as ‘critical’. Maria pushes back, explaining that the process of producing AntiBod is not 
always reliable and the antibodies themselves are still somewhat ‘uncertain’ (Sci1). Helen 
asserts that only if the process were made reliable, and the antibodies more highly specified, 
would other scientists buy them. The outcome of this contestation is that understanding and 
improving the production process for AntiBod is now important, for both scientific 
development and IP protection; as important as AntiBod itself. This identifies the science that 
must now be done, and the evidence that must be collected. It shifts Maria’s focus to ‘the market 
for the production of other antibodies’ and to new questions: ‘who else is producing 
antibodies? How are they doing it? How is AntiBod’s process different?’ (SBC4). 
Another outcome is an amended grant application that now says ‘more about the business 
model and who this is likely to be of interest to [the market]’ (F1). The meeting provides Maria 
with guidance for further market research using the competitor intelligence bioscience data, 
Medtrackiv, which details ‘all antibody producers in the market’ (SBC4). Finally, there is an 
instruction to ‘secure your intellectual property [IP] ASAP! [As Soon As Possible]’ (SBC4). 
The contestation reveals that the IP probably belongs to Sci1’s employing institution. Both 
market intelligence and IP associated with AntiBod have been made valuable. 
C3: Contesting the Institution’s IP Ownership (Feb 2015) 
Maria meets with her Head of Department (HoD) and a Technology Transfer Officer (TTO) 
from her academic institution. The TTO explains that as Maria has created new materials 
[AntiBod] which might help in creating ‘a therapeutic’, AntiBod and its production process are 
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patentable. If the ‘expensive work’ (TTO2) of securing a patent was successful, then the next 
stage for the TTO would be to try to partner with industry, probably ‘big pharma’, to do clinical 
trials. However, the TTO’s opinion is that AntiBod is not worth patenting as there is no proof-
of-concept data to show that AntiBod can be reliably reproduced. Since further development is 
needed to stabilise the process, the HoD has no objections to surrendering IP ownership to 
Maria but tensions emerge about who will be responsible for the costs of this work, in terms of 
both time and lab resources. The meeting concludes with the agreement that the TTO will 
pursue this with higher authorities in the institution. This is a protracted contestation because 
the IP to be ‘given away… has to be specified, much as a patent would be’ (TTO2). This 
contestation extends over eight months before Maria tells us ‘I have the letter …I have full 
ownership of the IP!’ What is significant in this contestation is that the TTO’s evaluation that 
AntiBod was not worth patenting is what makes the scientific discovery valuable to Maria, and 
in so doing holds AntiBod in place in the marketization process. The IP specification enables 
the calculation of AntiBod’s market value. 
C4: Contesting AntiBod’s Business Model (April 2015) 
SBC organizes a business modelling workshop for its tenants. The workshop instructor uses 
the Business Model Canvasv (Osterwalder and Pigneur 2010), and explains to Maria how this 
framework asks questions of AntiBod’s research programme, which must generate data that 
evidences the validity and value of AntiBod and its production process. Key activities, 
resources, partners, value propositions, customer relationships, channels to market, customer 
segments, and cost structures are used to represent ‘the known and the unknown, the real and 
the imagined’ (SBC3). Maria is pushed to explain how these business elements combine to 
generate revenue. There are tensions as Maria struggles. Other participants (all SBC tenants) 
contribute to the discussion, and consider their own business model ‘challenges’. Later, Maria 
reflects on what she does and doesn’t yet know about the ‘superior antibodies’, together with 
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the more detailed market overview she is working on, to create the ‘persuasive case’ for another 
grant application. An outcome of this contestation is that Maria has a more detailed narrative 
about how AntiBod will be developed, where the initial resources are likely to come from, and 
what will be needed, but the idea of ‘customers’ is still vague. She now talks about the 
importance of ‘investors’ and how she might use the business model to engage them. 
C5: Contesting the Connection with the Therapeutics Market (June 2015) 
Maria presents her new business model (BM2) to the SBC panel, which includes managers 
from Ely Lilyvi, two industrial consultants, two other bioscience entrepreneurs and Maria’s 
mentor from SBC. BM2 takes the form of a 14-slide presentation titled: ‘Developing superior 
antibodies by a novel integrative screening platform’. The business model is presented in terms 
of ‘the problem’, ‘the solution’, and ‘the opportunity’, incorporating scientific images of 
antibodies. Richer descriptions of the antibodies and the process by which these ‘superior 
antibodies’ are made ‘reliable’ and ‘highly specified’, circulate amongst the panel (Figure 3).  
The antibodies are developing their own identity as important actors. 
BM2 reframes the market. The previous description had been ‘the market for diagnostic 
and research antibodies’. The reframed market is referred to as ‘the market for antibodies’ 
incorporating three distinct market segments: the research antibody market ($2bn with 400 
antibody companies worldwide); the diagnostic antibody market ($8bn with 60 diagnostic 
companies worldwide); and therapeutic antibody market ($70bn). The size of each market is 
evidenced with citations from peer-reviewed scientific journals. The presentation provokes 
some excitement about the opportunity to engage with the ‘much larger therapeutics market’ 
and the panel push Maria to answer difficult questions about how this might be done. She 
doesn’t have answers but acknowledges the significance: ‘… so it’s a much bigger market and 
much more important investors are interested…’ A panel member explains, ‘if you can connect 




INSERT FIGURE 3 HERE 
---------------------------------- 
One panel member suggests meeting the GSK antibody group, to help Maria develop the 
business model: ‘they [GSK] will be able to tell you exactly what you’d need [data] to convince 
them….’ (P3). The suggestion receives strong support, as panel members recommend questions 
to put to GSK.  
The outcome of this contestation is that the group have imagined a connection between 
AntiBod and the S70bn therapeutics market. This would significantly raise the value of 
AntiBod and its production and specification process. The possible connection to GSK could 
open up an opportunity for partnership or exchange – Maria could sell AntiBod to GSK. 
Martino (SBC1) makes a call to GSK to fix the meeting. GSK are invoked as the market actor 
that can establish clear routes to economic value. 
C6: Contesting the Scientific Requirements of the Therapeutics Market (July 2015) 
The GSK meeting takes place a month after the expert panel, and Maria makes her presentation. 
The conversation focuses on ‘the [therapeutic] target’. Maria explains why AntiBod is so 
significant for the health market by contrasting the impact of an existing drug therapy 
[chemotherapy] with that of an antibody therapy on a cancer target: 
‘…with chemotherapy it is not the case that there is a specific target. In 
chemotherapy it turns out that the tumours are more resistant to the toxicity of the 
chemotherapeutic agent than the healthy tissue - because tumours develop […] 
multi-drug resistance. So treatment is very complex and very difficult. This is why 
there has been a paradigm change towards antibody treatment.’ (Sci1) 
GSK suggest that the target ‘must be a target that people understand’. The therapeutic target 
HER2vii (breast cancer) is recommended. Maria should identify antibodies against this target: 
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‘…What I take home from this discussion [with GSK] is that for a proof of concept 
it’s best to use a target that is well understood in pharma. […] For example, HER2 
EGF receptor – all these receptors where a lot of data is available.’ (Sci1) 
The discussion raised important concerns about demonstrating AntiBod’s potential value:  
‘…so the data package that I have to get is proof-of-concept experiments, in order 
to go back to investors and say this is the technology we have, this is the proof-of-
concept experiment and this is the data …’ (Sci1) 
Maria sees the specific forms of data needed to make AntiBod valuable. The activities 
required to produce such data are now clearly specified and worth engaging in. 
‘what would be very important … would be to have data from a tumour mouse model 
- and what we are doing per se is with a set of antibodies, is go through tissue slices 
from cancer patients, tumour versus controls, to see if there is differential binding 
of antibodies to patient but not to control tissue.’ (Sci1) 
An outcome of this contestation was the third incarnation of the business model (BM3). The 
market and the science are reframed: the market as ‘much bigger’ and the science as ‘more 
tightly characterised and specified.’ (SCi1)  
CONCEPTUAL INTERPRETATION AND THEORETICAL IMPLICATIONS 
Our conceptual interpretations of the empirical analysis are synthesized into three theoretical 
observations, which describe: the characteristics of choreographed contestations (O1), the 
mechanisms through which they operate (O2) and how specific valuations are perform (O3). 
These observations and their conceptual underpinnings are synthesised in Figure 1, offering a 
visual representation of our key contributions. Below, we discuss the implications of each 
observation for existing theory in more detail.  
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O1: Scientific objects are transformed into marketable, economically valuable objects by 
a series of unfolding choreographed contestations at the nexus of social worlds. 
Conceptual interpretation: Our findings show how a series of choreographed contestations 
incrementally transform scientific discoveries into marketable, economically valuable objects. 
Contestations were not chance events; they were ‘choreographed’. Our conceptualisation of 
‘choreography’ is a nuanced yet crucial finding. Contestations at the nexus of social worlds 
enrol particular actors. Yet, the choreography of contestations does not imply that the sequence 
of contestations follows a plan that is determined a priori. Rather, from each contestation new 
matters of concern emerge, different forms of knowledge become valuable and worth 
investigating, and different market devices are created that suggest new valuation practices for 
later contestations: C2 was conceived as a grant application discussion, yet the importance of 
IP ownership and the scientific data needed to secure IP were the significant outcomes, leading 
to the next significant contestation.  
Only when considered collectively (and retrospectively), can the sequence of 
choreographed contestations be understood as a goal-oriented, programme of action (Latour 
1992) for the marketization of science (Figure 2); a process which progressively disentangles 
the science from its laboratory home and entangles it into the social worlds of markets.  While 
the long-term goal may be to transform science into a marketable object, how this is achieved 
only becomes apparent as each moment of valuation unfolds the next. Thus, choreographing 
(Doganova and Muniesa 2015) such contestations in an unfolding process of working out what 
is valued, offers a mechanism through which the dissonance created through the collision of 
discourses, symbols and understandings underpinning different social worlds can be surfaced 
productively and acted upon, one innovative step at a time.  
Theoretical implications: These findings extend existing research on the 
commercialization of science and market studies. While the commercialisation of science 
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literature focuses on the structural and resource conditions of science commercialization 
(Dodgson et al. 2011; Lockett et al. 2002; Roseira et al. 2014), and the need for specific skills 
and expertise of organizational ‘insiders’ (Lockett and Wright 2005, p.1047), research on 
markets takes an external, interactive view (Araujo 2007; Callon and Muniesa 2005). By 
drawing on social worlds theory (Clarke and Star 2008) to bridge these perspectives, we 
develop a nuanced conceptualisation of choreographed contestations as a critical mechanism 
for the marketization of science (Figure 1). In so doing we show how multiple and varied 
valuation practices of internal (Stark 2009) and external (Fisher et al. 2016) actors are brought 
to bear on the marketization of a scientific object through choreographed contestations. This 
acknowledges the generative interplay of market actors, spanning diverse social worlds, in 
creating the sequence of goal-directed actions that constitute the marketization of science. By 
introducing social worlds theory to the conceptualisation of choreographed contestations we 
emphasise the importance of diversity in the histories, norms and practices of actors that 
become enrolled in the marketization of science. Thus, we explain how managers can begin to 
organise productive market connections to generate development pathways through the 
valuations they peform (cf. Cooke 2001; Fisher et al. 2016; Rasmussen et al. 2011). 
O2: Valuations are framed and fixed by the choreographed contestations and market 
devices they use. 
Conceptual interpretation: The framing of valuations determines who or what is of 
concern and to be taken into account, while fixing holds those temporarily framed relations, 
objects, and ideas stable so that they can be collectively contested (Finch and Geiger 2011).  
We consider first the nature of the choreography that takes place prior to a contestation, and 
secondly the adoption and production of market devices both before and within a contestation.  
First the choreography frames and fixes the form the valuation takes: determining which 
market actors do the valuing, through which market devices. Thus, choreographed contestation 
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act as market encounters that value. In some instances, the choreography is tight, identifying 
very specific actors, practices and value outcomes: C4 took tenants through a well-structured 
business modelling process. In other instances, the choreography is much looser, creating more 
exploratory contestations: C5 brought together key individuals and social worlds in a loosely 
controlled exploration of possible next steps, where various experts could ask challenging 
questions as they calculated what was worth doing and with whom.  We also observed tight 
choreographies, which led to quite different outcomes to those imagined: the grant application 
contestation, C2, is an example of this.  In each case, the choreography frames and fixes the 
form the valuation takes: imagining and arranging contestations that bring multiple evaluative 
norms, principles and devices into play. 
Secondly, market devices frame and fix what is to be valued within each contestation; what 
is socially and economically valuable, and so worth doing. Framing and fixing, through the 
production of visual or discursive representations, enable actors to bring together valuing 
practices from different social worlds. Valuations are made by contesting these momentarily 
fixed and shared representations. In C1, the combined representations of the business, the 
science, and the market act as the instruments of valuation. Knowing what is being valued (e.g. 
the market for antibodies) generates an information search judged valuable (i.e. who are 
AntiBod’s competitors?). In each instance, market devices act through valuation practices to 
mutually constitute one another. Valuations frame the next steps worth pursuing, the market 
actors worth enrolling, and the new knowledge worth searching for.  In this way, valuations of 
knowledge hold the scientific ‘asset’ in a state of ambiguity so that it can first be made open to 
multiple ways of redefining, combining and deploying resources for its development, in a 
process of working out the next innovative steps. These practices are discussed in O3. 
Theoretical implications: The framing and fixing of valuations as a mechanism of 
marketization has important implications for research on the commercialization of science. We 
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complement extant research on the institutions of science commercialization such as property 
rights (Debackere and Veugelers 2005; Lockett et al. 2002; Lockett and Wright 2005), licencing 
agreements (Lockett and Wright 2005; Siegel et al. 2003) or networks (Baraldi et al. 2014; 
Walter et al. 2006), with understandings of the materials  and practices through which 
valuations are performed (Callon and Muniesa 2005; Pénet 2015; Pollock and D’Adderio 
2012). In so doing, we provide a deeper understanding of the co-ordination and performance 
of distributed marketization work. Because the expertise required for marketization is 
distributed across multiple markets, social worlds, devices, and time (in the emergent nature of 
choreographed contestations), the need to co-ordinate and manage collective efforts of 
valuation are critical. Framing and fixing valuations enables mini market encounters to 
collectively experiment and test taken-for-granted market and scientific facts and norms, and 
opens new opportunities for market action. 
The notion of framing and fixing valuations also has implications for how academic spin-
offs are valued. Extant research problematizes current spin-off valuation practices, warning that 
using historical, forecasted or comparable IP development costs to calculate start-up value 
disconnects them from market value opportunities (Carte 2005; Clarysse et al. 2007). This is 
problematic because public or ‘soft’ funds skew development costs (Moray and Clarysse 2005; 
Wright et al. 2006), inflating early capital valuations, potentially deterring future investment 
(Clarysse et al. 2007). In contrast, our framework suggests how market-focussed 
representations, business models in particular can be used to frame and fix what is to be taken 
into account when valuing the business, in ways that open up connections to multiple market 
opportunities, enabling multiple market actors to calculate and contest such valuations. Our 
claim is that business models do more than ‘capture value’ through their representation of an 
‘architecture of the revenue’ (Chesbrough and Rosenbloom 2002, p.529). Rather, using 
business models as valuation devices shifts us away from historical development cost analysis, 
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to focus instead on emergent, future market connections and potential market share as a basis 
for valuation. This performative view of valuation assumes the co-production of powerful, 
shared imaginings represented in business models, which shape the unfolding actions of 
investors and other market actors as academic spin-offs are valued. 
O3: Valuations are generated by holding market devices in dialogue, with each other and 
with multiple social worlds. 
Conceptual interpretation: Our analysis reveals how new valuations are generated. The 
production of new valuations, both for the scientific discovery and for the activities that make 
the discovery valuable to specific market actors, are a central part of the marketization process. 
In each choreographed contestation, market actors hold multiple market devices in dialogue: 
(a) with each other: contesting market and scientific knowledge, raising concerns and 
generating new directions for their inquiry; and (b) with multiple social worlds: to explore 
alternative interpretations and framing of problems and challenges. For instance, C1 holds three 
market devices in dialogue (the science, the market and the business model), framing the 
specific concerns associated with three social worlds. This contestation produces new 
valuations: of potential markets, of competitors, and the importance of identifying new 
questions as AntiBod begins to disentangle from the small market of diagnostics and research 
antibodies, and entangle into the larger markets of therapeutics and market investors. In other 
contestations, the valuing process reveals tensions: in C3 conflict threatens as our scientist and 
her institution work out what the AntiBod is worth, who it might be of value to, and the work 
needed to realise that value. There is no consensus here, but this ambiguity enables Maria to 
secure the IP.  
Thus, contesting one market device, by holding it against other social worlds and market 
devices, enables actors to collectively produce new valuations that take into account the 
plurality of valuing principles at play, without requiring consensus. Such contestations can hold 
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key valuation devices in a state of constructive ambiguity, producing generative tensions that 
disrupt market categories by reimagining and reassembling resources. 
Theoretical implications: While the commercialisation of science literature goes some way 
to recognising the challenges and tensions typically experienced by academic-entrepreneurs 
(Perkmann et al. 2013; Siegel et al. 2003; Siegel and Wright 2015a), our research goes a step 
further. In combining market studies (Callon and Muniesa 2005; Kjellberg et al. 2015) and 
social worlds theory (Clarke and Star 2008), we foreground the role of market devices in the 
‘disentangling’ of scientific discoveries from the social world in which they were produced and 
entangling them in the social world of markets. We have seen how the practices that span social 
worlds disrupt and change them both, through moves to re-organise market interactions at their 
nexus. This observation offers a nuanced view of market devices in practice; in the production 
of valuations. It also explains the process by which the market devices are transformed. In so 
doing, we extend Grimaldi et al.’s (2011) and Perkmann et al.’s (2013) understanding of the 
work of academic-entrepreneurs by showing how they engage collectively, with other market 
actors, in the substantive work of transforming both science and markets through valuation 
practices: re-searching and re-presenting market and scientific knowledge in ways that make 
scientific discoveries valuable to specific groups of market actors. We see how they forge 
powerful associations not only between the scientific discovery and the concerns of broader 
social arenas, but also with the concerns of multiple market actors.  
CONCLUSIONS: Theories from the Lab to Future Research 
Based on the accepted premise that market connections are central to the commercialisation of 
science (Cooke 2001), we theorize the marketization of science. In so doing, we advance extant 
research on the commercialization of science by recognizing that the valuation of scientific 
discoveries occurs in market encounters at the nexus of social worlds, through what we call 
choreographed contestations. Choreographed contestations challenge what is collectively 
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valued - socially and economically, now and in the future – through a process of actors 
collectively working out what needs doing to transform both the scientific discovery and the 
market in relation to one another, so that exchange can happen. Our analysis reveals the 
characteristics of choreographed contestations (O1), the mechanisms through which they 
operate (O2) and explains how specific valuations are performed (O3). By presenting a 
framework for choreographed contestation and by identifying the associated valuation 
practices, we hope to stimulate further inquiry into the dynamics of market interactions with 
scientific discoveries.  
A limitation of our study is that data collection began at the point of incubation. We 
encourage research that analyses commercialization across multiple sites over longer periods, 
to capture the different institutional regimes that influence the nexus of social worlds. Our 
approach also neglects non-bioscience settings, where different social worlds, market devices 
and valuation practices may be implicated in marketization. We encourage future research to 
adopt a comparative approach, examining multiple discoveries across sectors, to identify 
context-dependent patterns of choreographed contestations. Despite these limitations we think 
our theories from the lab have broader implications for future research. 
The incubator site itself raises interesting questions about the changing form of academic 
entrepreneurship (Siegel and Wright 2015a). When we looked at the commercialization of 
science literature, many studies focused on university incubators (Jamil et al. 2015; Kolympiris 
and Klein 2017). SBC is different. We argue that the practices they adopt to make scientific 
discoveries valuable have implications for how incubators themselves are made valuable. We 
agree that extant measures of incubation success are lacking (Siegel and Wright 2015b), and 
argue that the study of valuation practices stands to make an important contribution to the 
development of performance management approaches for these new institutional forms of 
incubation. Only by valuing the management practices needed to choreograph contestations as 
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innovative and productive market encounters, do we stand a chance of developing 
accountability practices that perform the kinds of incubation and entrepreneurship we need. We 
see this as a valuable opportunity for future research. 
Our conceptualisation of the marketization of science adopts a performative view, seeing 
markets as the coordination of distributed agencies, where theoretical and practical knowledge 
and skills develop in an unending process of designing and managing markets (Çalışkan and 
Callon 2010). While our focus is on how a scientific discovery is made valuable, our findings 
also reveal the role of the academic-entrepreneurs and others in making this happen. We argue 
that the practices they perform are likely to change institutions, but our focus here is a specific 
institutional form - markets. Exploring how these practices are beginning to change universities 
and other associated institutions seems worthwhile.  Other studies have begun to explore this 
ground, considering commercialization and other forms of engagement, where individuals play 
a critical role in change (Perkmann et al. 2013).  By conceptualising these actors as institutional 
entrepreneurs - ‘…who have an interest in particular institutional arrangements and who 
leverage resources to create new institutions or to transform existing ones’ (Maguire et al. 2004, 
p.657) - we see opportunities to study how, collectively, actors create new systems of meaning 
that tie the functioning of disparate sets of institutions together (Garud et al. 2002). While these 
insights go beyond the scope of this paper, we hope that our theory from the lab inspires further 
research in this field. 
REFERENCES 
Antal, A. B., M. Hutter, and D. Stark. 2015. "Moments of Valuation." Oxford: Oxford 
University Press. 
Araujo, L. 2007. "Markets, market-making and marketing." Marketing Theory, 7, 221-26. 
Araujo, L., and J. Pels. 2015. "Marketization and its limits." DECISION, 42, 451-56. 
Azimont, F., and L. Araujo. 2007. "Category reviews as market-shaping events." Industrial 
Marketing Management, 36, 849-60. 
35 
 
Baraldi, E., M. Ingemansson, and A. Launberg. 2014. "Controlling the commercialisation of 
science across inter-organisational borders: Four cases from two major Swedish 
universities." Industrial Marketing Management, 43, 382-91. 
Baszanger, I. 1998. Inventing pain medicine: From the laboratory to the clinic. New Brunswick 
NJ: Rutgers University Press. 
Bordeaux, J., A. W. Welsh, S. Agarwal, E. Killiam, M. T. Baquero, J. A. Hanna, V. K. 
Anagnostou, and D. L. Rimm. 2010. "Antibody validation." BioTechniques, 48, 197-
209. 
Bruneel, J., T. Ratinho, B. Clarysse, and A. Groen. 2012. "The Evolution of Business 
Incubators: Comparing demand and supply of business incubation services across 
different incubator generations." Technovation, 32, 110-21. 
Bucher, R. 1962. "Pathology: A study of social movements within a profession." Social 
problems, 10, 40-51. 
Çalışkan, K., and M. Callon. 2010. "Economization, part 2: a research programme for the study 
of markets." Economy and Society, 39, 1-32. 
Callon, M., and F. Muniesa. 2005. "Peripheral Vision: Economic Markets as Calculative 
Collective Devices." Organisation Studies, 26, 1229-50. 
Carte, N. 2005. "The maximum achievable profit method of patent valuation." International 
Journal of Innovation and Technology Management, 2, 135-51. 
Charmaz, K. 2006. "The power of names." Journal of Contemporary Ethnography, 35, 396-99. 
Chesbrough, H., and R. S. Rosenbloom. 2002. "The role of the business model in capturing 
value from innovation: evidence from Xerox Corporation's Technology Spin-off 
Companies." Industrial & Corporate Change, 11, 529-55. 
Clarke, A. E., and S. L. Star. 2008. "The social worlds framework: A theory/methods package." 
The handbook of science & technology studies, 3, 113-37. 
Clarysse, B., M. Wright, A. Lockett, P. Mustar, and M. Knockaert. 2007. "Academic spin-offs, 
formal technology transfer and capital raising." Industrial and Corporate Change, 16, 
609-40. 
Cochoy, F. 2009. "Driving a Shopping Cart from STS to Business, and the Other Way Round: 
On the Introduction of Shopping Carts in American Grocery Stores (1936-1959)." 
Organization, 16, 31-55. 
Cooke, P. 2001. "Biotechnology Clusters in the UK: Lessons from Localisation in the 
Commercialisation of Science." Small Business Economics, 17, 43-59. 
36 
 
Cuatrecasas, P. 2006. "Drug discovery in jeopardy." The Journal of Clinical Investigation, 116, 
2837-42. 
Debackere, K., and R. Veugelers. 2005. "The role of academic technology transfer 
organizations in improving industry science links." Research Policy, 34, 321-42. 
Denis, J.-L., A. Langley, and L. Rouleau. 2007. "Strategizing in pluralistic contexts: Rethinking 
theoretical frames." Human Relations, 60, 179-215. 
Dewey, J. 1938. Logic: The Theory of Inquiry. New York: Holt; London: Allen & Unwin. 
Dodgson, M., A. Hughes, J. Foster, and S. Metcalfe. 2011. "Systems thinking, market failure, 
and the development of innovation policy: The case of Australia." Research Policy, 40, 
1145-56. 
Doganova, L., and F. Muniesa. 2015. "Capitalization Devices." Pp. 109-25 in Making Things 
Valuable, edited by Martin Kornberger, Lise Justesen, Koed Anders Madsen, and Jan 
Mouritsen. Oxford: Oxford University Press. 
Dubois, A., and L.-E. Gadde. 2002. "Systematic combining: an abductive approach to case 
research." Journal of Business Research, 55, 553-60. 
Dussauge, I., C.-F. Helgesson, and F. Lee. 2015. Value practices in the life sciences and 
medicine: Oxford University Press, USA. 
Finch, J., and S. Geiger. 2011. "Constructing and contesting markets through the market 
object." Industrial Marketing Management, 40, 899-906. 
Fisher, G., S. Kotha, and A. Lahiri. 2016. "Changing with the times: An integrated view of 
identity, legitimacy, and new venture life cycles." Academy of Management Review, 41, 
383-409. 
Fujimura, J. H. 1996. Crafting science: A sociohistory of the quest for the genetics of cancer: 
Harvard University Press. 
Garud, R., S. Jain, and A. Kumaraswamy. 2002. "Institutional Entrepreneurship in the 
Sponsorship of Common Technological Standards: The Case of Sun Microsystems and 
Java." The Academy of Management Journal, 45, 196-214. 
Geertz, C. (Ed.). 1973. The Interpretation of Cultures: Selected Essays. New York: Basic 
Books. 
Geiger, S., D. Harrison, H. Kjellberg, and A. Mallard. 2014. Concerned Markets: Economic 
Ordering for Multiple Values Northampton, USA; Cheltenham, UK.: Edward Elgar 
Publishing. 
Grimaldi, R., M. Kenney, D. S. Siegel, and M. Wright. 2011. "30 years after Bayh–Dole: 
Reassessing academic entrepreneurship." Research Policy, 40, 1045-57. 
37 
 
Helgesson, C.-F., and F. Muniesa. 2013. "For what it’s worth: An introduction to valuation 
studies." Valuation Studies, 1, 1-10. 
Jamil, F., K. Ismail, and N. Mahmood. 2015. "A review of commercialization tools: University 
incubators and technology parks." International Journal of Economics and Financial 
Issues, 5. 
Kjellberg, H., F. Azimont, and E. Reid. 2015. "Market innovation processes: Balancing stability 
and change." Industrial Marketing Management, 44, 4-12. 
Kolympiris, C., and P. G. Klein. 2017. "The Effects of Academic incubators on university 
Innovation." Strategic Entrepreneurship Journal, 11, 145-70. 
Kornberger, M. 2017. "The Values of Strategy: Valuation Practices, Rivalry and Strategic 
Agency." Organization Studies, early cite (online), doi:10.1177/0170840616685365. 
Kornberger, M., L. Justesen, K. A. Madsen, and J. Mouritsen. 2015. "Making things valuable." 
Pp. 1-17 in Making Things Valuable, edited by Martin Kornberger, Lise Justesen, Koed 
Anders Madsen, and Jan Mouritsen. Oxford, UK: Oxford University Press, USA. 
Langley, A. 1999. "Strategies for theorizing from process data." Academy of Management 
Review, 24, 691-710. 
—. 2007. "Process thinking in strategic organization." Strategic Organization, 5, 271-82. 
Langley, A., C. Smallman, H. Tsoukas, and A. H. V. d. Ven. 2013. "Process studies of change 
in organization and management: Unveiling temporality, activity and flow." Academy 
of Management Journal, 56, 1-13. 
Latour, B. 1987. Science in Action. Cambridge, Massachusetts: Harvard University Press. 
—. 1992. "Where are the missing Masses? The Sociology of a few mundane artifacts." Pp. 225-
58 in Shaping technology Building society, edited by W. E.l Bijker and J. Law. 
Cambridge M.A.: MIT Press. 
Lockett, A., A. Vohora, and M. Wright. 2002. "Universities as incubators without Walls." The 
International Journal of Entrepreneurship and Innovation, 3, 245-56. 
Lockett, A., and M. Wright. 2005. "Resources, capabilities, risk capital and the creation of 
university spin-out companies." Research Policy, 34, 1043-57. 
Lockett, A., M. Wright, and S. Franklin. 2003. "Technology transfer and universities' spin-out 
strategies." Small Business Economics, 20, 185-200. 
Loe, M. 2004. The Rise of Viagra: How the Little Blue Pill Changed Sex in America. NY: New 
York University Press. 
38 
 
Maguire, S., C. Hardy, and T. B. Lawrence. 2004. "Institutional Entrepreneurship in Emerging 
Fields: HIV/AIDS Treatment Advocacy in Canada." The Academy of Management 
Journal, 47, 657-79. 
Maitlis, S. 2005. "The social processes of organizational sensemaking." Academy of 
Management Journal, 48, 21-49. 
Mian, S., W. Lamine, and A. Fayolle. 2016. "Technology Business Incubation: An overview 
of the state of knowledge." Technovation, 50, 1-12. 
Moray, N., and B. Clarysse. 2005. "Institutional change and resource endowments to science-
based entrepreneurial firms." Research Policy, 34, 1010-27. 
Muniesa, F., Y. Millo, and M. Callon. 2007. "An Introduction to Market Devices." in Market 
Devices, edited by Michel Callon, Yuval Millo, and Fabian Muniesa. Oxford, London: 
Blackwell Publishing. 
Osta, W. A., Y. Chen, K. Mikhitarian, M. Mitas, M. Salem, Y. A. Hannun, D. J. Cole, and W. 
E. Gillanders. 2004. "EpCAM is overexpressed in breast cancer and is a potential target 
for breast cancer gene therapy." Cancer research, 64, 5818-24. 
Osterwalder, A., and Y. Pigneur. 2010. Business Model Generation. Hoboken, New Jersey, 
USA: John Wiley & Sons. 
Pénet, P. 2015. "Rating Report as Figuring Documents." Pp. 62-88 in Making Things Valuable, 
edited by Martin Kornberger, Lise Justesen, Koed Anders Madsen, and Jan Mouritsen. 
Oxford: Oxford University Press. 
Perkmann, M., V. Tartari, M. McKelvey, E. Autio, A. Broström, P. D’Este, R. Fini, A. Geuna, 
R. Grimaldi, A. Hughes, S. Krabel, M. Kitson, P. Llerena, F. Lissoni, A. Salter, and M. 
Sobrero. 2013. "Academic engagement and commercialisation: A review of the 
literature on university–industry relations." Research Policy, 42, 423-42. 
Pollock, N., and L. D’Adderio. 2012. "Give me a two-by-two matrix and I will create the 
market: Rankings, graphic visualisations and sociomateriality." Accounting, 
Organizations and Society, 37, 565-86. 
Rasmussen, E., S. Mosey, and M. Wright. 2011. "The evolution of entrepreneurial 
competencies: A longitudinal study of university spin‐off venture emergence." Journal 
of Management Studies, 48, 1314-45. 
Roseira, C., C. Ramos, F. Maia, and S. Henneberg. 2014. "Understanding Incubator Value A 
Network Approach to University Incubators." University of Porto-FEP-School of 
Economics and Management. 
39 
 
Siegel, D. S., D. Waldman, and A. Link. 2003. "Assessing the impact of organizational 
practices on the relative productivity of university technology transfer offices: an 
exploratory study." Research Policy, 32, 27-48. 
Siegel, D. S., and M. Wright. 2015a. "Academic entrepreneurship: time for a rethink?" British 
Journal of Management, 26, 582-95. 
—. 2015b. "University technology transfer offices, licensing, and start-ups." Pp. 1-40 in 
Chicago handbook of university technology transfer and academic entrepreneurship, 
edited by Albert N Link, Donald S Siegel, and Mike Wright. Chicago, IL: University 
of Chicago Press. 
Stark, D. 2000. "For a Sociology of Worth." Pp. 1-10. Berlin: Keynote address for the Meetings 
of the European Association of Evolutionary Political Economy. 
—. 2009. The Sense of Dissonance: Accounts of Worth in Economic Life. Princeton, New 
Jersey: Prenceton University Press. 
Strauss, A. 1978. "A social world perspective." Studies in symbolic interaction, 1, 119-28. 
Vohora, A., M. Wright, and A. Lockett. 2004. "Critical junctures in the development of 
university high-tech spinout companies." Research Policy, 33, 147-75. 
Walter, A., M. Auer, and T. Ritter. 2006. "The impact of network capabilities and 
entrepreneurial orientation on university spin-off performance." Journal of Business 
Venturing, 21, 541-67. 
Wright, M., A. Lockett, B. Clarysse, and M. Binks. 2006. "University spin-out companies and 
venture capital." Research Policy, 35, 481-501. 



















Figure 3: Slides 6 and 7 from Business Model BM2 
Note: These slides have been altered to provide the reader with an impression of the information as it was presented but to protect the 







Table I: Summary of Data Collected 
Timing Interviews* Documents & Videos  Events attended 
July  
2014  
5x Interviews with SBC 
tenants (academic-
entrepreneurs and academic 
scientists) 
Tenants’ Documents that represent 
tenants’ business models 
Press Releases, white papers  
 
3x Interviews with SBC 
Managers  
SBC documents that represent SBCs 
understanding of its business model; 
strategy documents and slide decks of 
presentation to board 
Workshop hosted at SBC 
on ‘The Convergence 
Agenda’ 
2x Follow-up video interviews 
with SBC tenants (scientists) 
Further documents that represent 
SBC’s business model; press release; 





5x Interviews with SBC 
tenants (scientists) 
Press releases, newsletters, press 
cuttings, official notes produced from 
workshop 
 
3x Interviews with SBC 
Managers.  
Grant Forms  
4x Interviews with workshop 
attendees: entrepreneurs in the 
biotech/bio-pharma area 
Summary document from 
‘Convergence Agenda’ workshop; 
White papers from Open Innovation 
 
2x Follow-up video interviews 
with workshop attendees in 




5x Interviews with SBC 
tenants (including AntiBod 
Scientist)  
3x Interviews with SBC 
Managers 
Revised business models of Tenants 
AntiBod Summary document 
New SBC strategy documents, and 
pitch for 2nd phase of campus 
expansion 
Revised business model of SBC 
Open Innovation Summit: 
hosted by SBC, with 200 key 




3x Follow-up video 
interviews: AntiBod, Scinovo, 
Funder 
AntiBod BM1; Grant Forms; SBC 
Newsletter 





3x Interviews with SBC 
tenants (academic-
entrepreneurs and academic 
scientists including AntiBod) 
Activities audit report commissioned 
by SBC, independent consultant 
SBC Newsletter; Patent application 
form  
 
June & July 
2015 
 
3x Follow-up interviews SBC 
Managers, Scinovo,  AntiBod 
Slide Decks presented at recent 
events; AntiBod BM2 






2x Follow-up interviews with 
SBC Managers  
2x Follow-up interviews with 
tenants/AntiBod;  
7x interviews with academic 
scientists/TTOs/HoD/Scinovo 
Revised business models of tenants 
AntiBod BM3 
SBC Press Releases 




 Open Innovation Summit videos; 
White paper, slide decks presented at 
summit. 
Open Innovation Summit: 
hosted by SBC, with 140 key 
industry players & start-ups in 
attendance. 
Note: Interview* quotes used in this paper are represented as T, SBC, or GSK for example, to provide some indication of the 
role of the interviewee but to provide a degree of anonymity too. Names have been changed to protect the identity of some of 
the participants. BM1 refers to the different versions of the business model generated by our scientist Sci1.
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Social worlds Market devices used in 
valuation practices  
Intersection of social worlds through the 
performance of valuation practices  
Valuation outcomes & market devices generated 
through contestation  




 Maria (Sci1) 
 SBC CEO and 
Mentor (SBC1) 
Science Scientific representation of 
‘Superior Antibodies’ 
 Sci1 arrives with a rudimentary 
knowledge of market and entrepreneurship 
social worlds, and associated market 
devices (i.e. how to talk about a market; 
how to present a business idea).  
 SBC1 contests multiple aspects of Sci1’s 
market knowledge as represented in her 
summary document: he queries the claims 
relating to the market scope and scale, and 
challenges the scientist to think further 
about her business model, and how it fits 
with this market. 
 SBC1 asserts the value of further 
interactions across multiple social worlds: 
With the entrepreneur in residence, other 
SBC-based antibody scientists, and a 
wider market search. 
 The scientist judges the value of SBC 
incubation, the community of antibody 
companies there, and in the ‘bigger picture’ 
knowledge of SBC1. 
 The need for a broader knowledge of the 
market is now deemed valuable to better 
understand potential futures for AntiBod. 
Associated Market Devices: 
 Tenancy at SBC is a device that suggests 
legitimacy as an entrepreneurial scientist, and 
identifies AntiBod as a discovery undergoing 
marketization. 
 Diagram scribbled in the margins by the 
scientist (informed by the language of 
markets and entrepreneurship) becomes the 
‘1st incarnation of the Business Model.’ 
Market ‘The scope and scale of the 
market opportunity’ 
Competition within market 
Entrepreneurship ‘Summary’: the business 
idea, the science that needs 
developing and the markets 
that the goods/science will 
be of value to: referred to by 
SBC as ‘the business model’ 
C2: (Feb 2015) 
Contesting how 
the market is 
represented in a 
grant application 
 Maria (Sci1) 
 Funding Body 
(F2) 
 Entrepreneur in 
Residence 
(SBC4) 
Science Scientific representation of 
the antibody specification 
and potential for use in 
clinical testing 
 The initial intention is to identify valuable 
market-knowledge for success with an 
Innovate UK grant application. 
 Through this collective search activity, 
linked predominantly to market concerns, 
the importance of establishing IP 
ownership emerges from the 
entrepreneurship social world – the 
scientist must ensure that she, not her 
employer, captures the value from the 
science. 
 These entrepreneurial and market 
concerns about asset ownership impact on 
the Scientific world: for IP to be created, 
further lab work must be done to specify 
what AntiBod is and how it is produced. 
 Company formation and IP ownership are 
established as valuable to Sci1, in relation to 
investability and asset protection. 
 Research into other antibodies in the market, 
and possible routes to market, becomes 
valuable. 
Associated Market Devices: 
 New specification of the market object: 
synthetic antibodies and the process of their 
production. 
 New assemblages of market knowledge are to 
be created, incorporating a comprehensive 
study of rival antibodies, through Medtrack. 
Market Smart Grant Competition 
(with scientific discovery, 
business model and IP 
sections) 
Entrepreneurship Specification of Routes to 
Market 




Table II. Analysis of the Choreographed Contestations of Social Worlds Designed to Value, the Market Devices Invoked and Outcomes (cont'd) 
Contestation & 
actors 
Social worlds Market devices used in 
valuation practices  
Intersection of social worlds through the 
performance of valuation practices  
Valuation outcomes & market devices generated 
through contestation  





 Maria (Sci1) 
 Maria’s HoD 
 Tech. Transfer 
Office (TTO2) 
 
Science Specification of antibodies 
Stabilized production 
process 
 Patenting AntiBod is presented as a step 
towards establishing its place in the 
market for ‘big pharma’ partnership. 
However, the IP specification work 
requires additional scientific activity, at 
significant cost. 
 The required investment in this work, 
whilst being seen as worthwhile and 
valuable by the increasingly 
entrepreneurial Sci1, is a barrier to 
progress for her institution.    
 AntiBod becomes ‘not valuable’ to the 
academic institution, based on their 
assessment of the costs, risks and rewards of 
the patenting process. 
 Non-value to academia is an important source 
of value to Sci1, whose principal concern now 
is to own and protect this potentially valuable 
IP. 
Associated Market Devices: 
 The Letter confirms willingness to release IP. 
 The patenting process shifts from being 
invoked as a barrier by the institution (due to 
expense), to a key aspect of value protection 
for Sci1. 
 Specifying the IP generates a device that 
enables Sci1 to begin working out AntiBod’s 
potential market value. 
C4: (Apr 2015) 
Contesting 
AntiBod’s 
business model in 
a workshop for 
academic-
entrepreneurs 
 Maria (Sci1) 
 Other SBC 
tenants 
 Facilitator 
Science Summarised representations 
of AntiBod’s research 
development programme 
 The practice of business modelling using 
the Business Model Canvas is a well-
established entrepreneurial activity that 
helps individuals to identify gaps in 
knowledge, while also seeing how the 
different elements might integrate. 
 It is the integrative nature of the BM 
Canvas workshop that encourages Sci1 to 
think in a more holistic way, across 
multiple social worlds, to identify the 
route through which AntiBod might 
become revenue generating. 
 This entrepreneurial activity encourages 
Sci1 to consider the valuation practices of 
investors, and to anticipate related future 
contestations. 
 Completeness of the business model, with 
further specification of planned activities and 
market opportunities, is now seen by Sci1 as a 
valuable source of understanding, and a 
communication device. 
Associated Market Devices: 
 The next incarnation of the business model is 
being generated through the interactions in 
this contestation, with further work required. 
 The ‘persuasive case’ is being generated, and 
is significant in that it integrates the scientific, 
entrepreneurial and market knowledge 
necessary to evidence potential economic 
value to investors. 
Entrepreneurship Business Model Canvas, 
which in turn requires 
multiple inputs including:    
Analysis of resources 
potentially available as well 
as potential markets 
Market Well-evidenced descriptions 
of three markets and their 
sizes: research antibody 
market, diagnostic antibody 




Table II. Analysis of the Choreographed Contestations of Social Worlds Designed to Value, the Market Devices Invoked and Outcomes (cont'd) 
Contestation & 
actors 
Social worlds Market devices used in 
valuation practices  
Intersection of social worlds through the 
performance of valuation practices  
Valuation outcomes & market devices generated 
through contestation  







 Maria (Sci1) 
 SBC 




Science Rich descriptions of 
synthetic antibodies 
Rich descriptions of the 
process of production of 
synthetic antibodies 
 The BM slide deck is an important 
entrepreneurial device, constituted of 
multiple elements of scientific and market 
knowledge, woven together to evidence 
the value of AntiBod, the legitimacy of 
Sci1, and the routes through which value 
might be realized (i.e. ‘much larger 
therapeutics market’). 
 The discussions span the social worlds of 
science (what science still needs to be 
done) and markets it is of interest to. 
 The combination of expertise from across 
these social worlds allows judgements to 
be made about which markets to pursue, 
and which next steps are valuable. 
 The value of doing therapeutic target search 
work is established, based on the reframing of 
the potential market. 
 AntiBod is now seen as having sufficient 
potential value to put it in front of GSK. 
Simultaneously the value of GSK’s antibody 
expertise to the scientific work is identified. 
Associated Market Devices: 
 The specific data required to evidence 
AntiBod’s value becomes an important device 
that needs to be generated through interaction 
with GSK. 
 GSK Antibody Group becomes a powerful 
science and market shaping device, as a 
known source of expertise and a potential 
route to the realisation of economic value 
from AntiBod. 
Market Well-evidenced descriptions 
of three markets and their 
sizes: research antibody 
market, diagnostic antibody 
market, and therapeutic 
antibody market. 
Entrepreneurship Comprehensive BM slide 
deck aimed at evidencing the 
authenticity of AntiBod as 
an investable market object 










Science Contrast between alternative 
therapeutic approaches and 
the ‘paradigm change’ 
towards antibodies 
 The GSK scientists offer Sci1 a more 
tightly defined understanding of the 
scientific work that needs to be carried 
out, and why. 
 The connection between potential market 
value and very specific forms of scientific 
work is now made explicit. 
 Value of proof-of-concept requires 
comparability to existing and FDA approved 
antibodies. 
 Economic value of AntiBod and the IP is now 
specifically linked to its medical value as a 
potential cancer treatment. 
Associated Market Devices: 
 Business Model 3 connects presentations of 
more specific scientific & market knowledge 
to create a clearer route for advancement. 
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Table III Summary of Theoretical Contributions 
Observations Interpretation of findings Theoretical contribution 
O1: Scientific objects are transformed into 
marketable, economically valuable objects 
by a series of unfolding choreographed 
contestations at the nexus of social worlds. 
 Choreographed contestations are the purposeful 
bringing together of multiple actors at the nexus of 
social worlds – they are not chance events.  
 The sequence of contestations cannot be pre-
determined as each one reveals valuable next steps. 
 Collectively and retrospectively a sequence of 
choreographed contestations can be understood as a 
programme of action for the marketization of science. 
 Social worlds theory (Clarke and Star, 2008) provides a bridge 
between commercialization of science and market studies literatures, 
yielding new insights into the marketization of science. 
 The generative interplay of actors at the nexus of social worlds gives 
insight into the role of different actors’ norms, histories and practices 
in choreographed contestations (cf. Doganova and Muniesa, 2015), 
which collectively form a sequence of goal-directed actions. 
 Choreographed contestations rely on the multiple and varied valuation 
practices of internal (Stark 2009) and external (Fisher et al., 2016) 
actors to organise productive market connections and development 
pathways. 
O2: Valuations are framed and fixed by the 
choreographed contestations and market 
devices they use. 
 Framing reveals who or what is of concern and to be 
taken into account, while fixing holds ideas, objects and 
relations stable.  
 Choreography frames and fixes the form the valuation 
will take as actors determine what will be valued, by 
whom, and through which devices.  
 Market devices frame and fix what is to be valued, as 
their representation enable actors to bring together 
diverse valuing practices from different social worlds. 
 Framing and fixing offers a new perspective on the mechanisms 
through which commercialization proceeds. 
 Framing and fixing through the choreography of contestations 
enables the co-ordination of distributed expertise, enabling critical 
moments of collective valuation to take place. 
 This understanding of the materials and practices through which 
valuations are performed complements extant research concerned 
with the institutional conditions of science commercialization 
(Baraldi et al., 2014; Debackere and Veugelers, 2005; Lockett et al., 
2002; Lockett and Wright, 2005; Walter et al., 2006)  
O3: Valuations are generated by holding 
market devices in dialogue, with each other 
and with multiple social worlds 
 We reveal how new valuations are generated in the 
process of science marketization. 
 Actors hold market devices in dialogue with each other 
during contestations to generate new directions for 
inquiry. 
 These valuations draw on devices and practices from 
multiple social worlds, allowing alternative 
interpretations and problem framings to be explored. 
 
 The role of market devices in ‘disentangling’ scientific discoveries 
from the lab, and entangling them into the world of markets, extends 
understandings of the challenges faced by academic entrepreneurs 
(Siegel and Wright, 2015; Siegel et al., 2003; Perkmann et al. 2013). 
 We show the role played by market devices in valuation practices, 
highlighting the importance of interactions at the nexus of social 
worlds to extend our extant understanding of the work performed by 
academic entrepreneurs (Grimaldi et al. 2011, Perkmann et al.2013) 
as they engage collectively, with other market actors, in the 









ii The Berkeley Innovation Forum is a membership organization hosted by Dr. Henry Chesbrough, Faculty 
Director of the Garwood Center for Corporate Innovation. Professor Chesbrough has become a world renowned 
authority on the topic of open innovation. 
iii Innovate UK is UK’s innovation agency: an executive non-departmental public body, sponsored by the 
Department for Business Energy & Industrial Strategy. 
iv Medtrack follows all the companies and people that touch Healthcare: financing, drug discovery, 
manufacturing, contract manufacturing and development. Coverage spans discovery through patent expiry and 
loss of market exclusivity and generic entry. See: https://pharmaintelligence.informa.com/products-and-
services/data-and-analysis/medtrack 
v To see ‘the business model Canvas in 2 minutes’ visit http://www.businessmodelgeneration.com/canvas/bmc 
vi Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with 
offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 
1876.  
vii Human epidermal growth factor receptor 2 is a member of the human epidermal growth factor receptor 
(HER/EGFR/ERBB) family. Amplification or over-expression of this onco gene has been shown to play an 
important role in the development and progression of certain aggressive types of breast cancer. In recent years 
the protein has become an important biomarker and target of therapy for approximately 30% of breast 
cancer patients. 
                                                          
